Garrett M Fitzmaurice1, Stuart R Lipsitz2, Roger D Weiss3. 1. McLean Hospital,115 Mill Street, Belmont, MA 02478, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: fitzmaur@hsph.harvard.edu. 2. Brigham and Women's Hospital, 1620 Tremont Street, Boston, MA 02120, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. 3. McLean Hospital,115 Mill Street, Belmont, MA 02478, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
Abstract
BACKGROUND: To date, the US Food and Drug Administration (FDA) requires drug use disorder trials developing new medications to use abstinence, a clinically meaningful endpoint, as the primary outcome. Although abstinence is the gold standard, only a relatively small percentage of participants in drug use disorder trials ever achieve this endpoint. This has prompted clinical trialists to consider quantitative measures of frequency of use, recognizing that some reductions in drug use that fall short of complete abstinence may potentially represent clinically important improvements. While much of the discussion concerning alternative outcomes to abstinence has focused on their clinical relevance, there are important statistical considerations that should also be taken into account. PURPOSE: In this paper, we demonstrate and highlight the degree to which use of a quantitative measure of frequency of use, relative to a binary measure of abstinence, yields a very discernible increase in statistical power for assessing efficacy or effectiveness of treatments for drug use disorders. CONCLUSION: While it is well established that dichotomizing a quantitative measure invariably results in loss of statistical power, what is less well recognized is the degree of loss in the context of drug use disorder trials. In some cases, the required sample size must be almost doubled to achieve the same level of power.
BACKGROUND: To date, the US Food and Drug Administration (FDA) requires drug use disorder trials developing new medications to use abstinence, a clinically meaningful endpoint, as the primary outcome. Although abstinence is the gold standard, only a relatively small percentage of participants in drug use disorder trials ever achieve this endpoint. This has prompted clinical trialists to consider quantitative measures of frequency of use, recognizing that some reductions in drug use that fall short of complete abstinence may potentially represent clinically important improvements. While much of the discussion concerning alternative outcomes to abstinence has focused on their clinical relevance, there are important statistical considerations that should also be taken into account. PURPOSE: In this paper, we demonstrate and highlight the degree to which use of a quantitative measure of frequency of use, relative to a binary measure of abstinence, yields a very discernible increase in statistical power for assessing efficacy or effectiveness of treatments for drug use disorders. CONCLUSION: While it is well established that dichotomizing a quantitative measure invariably results in loss of statistical power, what is less well recognized is the degree of loss in the context of drug use disorder trials. In some cases, the required sample size must be almost doubled to achieve the same level of power.
Authors: Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson Journal: Addiction Date: 2011-10-07 Impact factor: 6.526
Authors: Dennis M Donovan; George E Bigelow; Gregory S Brigham; Kathleen M Carroll; Allan J Cohen; John G Gardin; John A Hamilton; Marilyn A Huestis; John R Hughes; Robert Lindblad; G Alan Marlatt; Kenzie L Preston; Jeffrey A Selzer; Eugene C Somoza; Paul G Wakim; Elizabeth A Wells Journal: Addiction Date: 2011-07-22 Impact factor: 6.526
Authors: Brian D Kiluk; Kathleen M Carroll; Amy Duhig; Daniel E Falk; Kyle Kampman; Shengan Lai; Raye Z Litten; David J McCann; Ivan D Montoya; Kenzie L Preston; Phil Skolnick; Constance Weisner; George Woody; Redonna Chandler; Michael J Detke; Kelly Dunn; Robert H Dworkin; Joanne Fertig; Jennifer Gewandter; F Gerard Moeller; Tatiana Ramey; Megan Ryan; Kenneth Silverman; Eric C Strain Journal: Drug Alcohol Depend Date: 2015-11-21 Impact factor: 4.492
Authors: Paul Crits-Christoph; Robert Gallop; Mary Beth Connolly Gibbons; Jaclyn S Sadicario; George Woody Journal: J Alcohol Drug Depend Date: 2013-03
Authors: Rachel L Tomko; Erin A McClure; Lindsay M Squeglia; Hayley Treloar Padovano; Aimee L McRae-Clark; Nathaniel L Baker; Matthew J Carpenter; Kevin M Gray Journal: Curr Opin Psychol Date: 2019-01-28
Authors: Megan Kirouac; Eric Kruger; Adam D Wilson; Kevin A Hallgren; Katie Witkiewitz Journal: Am J Drug Alcohol Abuse Date: 2019-03-14 Impact factor: 3.829
Authors: Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure Journal: Curr Addict Rep Date: 2019-11-19